Classification of Adenocarcinoma of the Esophagogastric Junction

Barrett Esophagus Clinical Trial

Official title:

Biologic Classification of Adenocarinoma of the Esophagus and Esophagogastric Junction (AEG) Using a Novel Data-driven System: Should it Replace or Compliment the Siewert Classification?

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04151524
• Other study ID #: SJH00002
• Status: Active, not recruiting
• Start date: October 23, 2019
• Est. completion date: February 1, 2020

Study information

• Verified date: November 2019
• Source: St. James's Hospital, Ireland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Siewert classification of oesophageal cancer is the standard approach in anatomically subdividing cancer of the lower oesohagus.

Description:

Retrospective review of tumour biology, pathological staging and outcomes in the participants based on Siewert classification. The investigators to scrutinise this scoring system to evaluate if it is indeed appropriate.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1658
• Est. completion date: February 1, 2020
• Est. primary completion date: December 25, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Adenocarcinoma
• Barrett Esophagus
• Esophageal Neoplasms
• Oesophagus Cancer
• Siewert Type I Adenocarcinoma of Esophagogastric Junction
• Siewert Type II Adenocarcinoma of Esophagogastric Junction
• Siewert Type III Adenocarcinoma of Esophagogastric Junction

Locations

Country	Name	City	State
Ireland	St. James's Hospital	Dublin 8	IE

Sponsors (1)

Lead Sponsor	Collaborator
St. James's Hospital, Ireland

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival		2 years